Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 6/20 | 0.46 |
| ▸ | MASP2 | O00187 | 3/20 | 0.44 |
| ▸ | KLK1 | P06870 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431903 | 1.00 | KLKB1 (0.46) | KLKB1MASP2KLK1NAMPTFPR2 | |
| SCHEMBL1431905 | 1.00 | KLKB1 (0.46) | KLKB1MASP2KLK1NAMPTFPR2 | |
| SCHEMBL1431700 | 0.89 | KLKB1 (0.49) | KLKB1MASP2KLK1FPR2FCER2 | |
| SCHEMBL3153048 | 0.89 | KLKB1 (0.49) | KLKB1MASP2KLK1FPR2FCER2 | |
| SCHEMBL1907929 | 0.87 | KLKB1 (0.49) | KLKB1MASP2KLK1NAMPTFPR2 | |
| SCHEMBL3149512 | 0.86 | MASP2 (0.47) | KLKB1MASP2KLK1NAMPTFPR2 | |
| SCHEMBL1431982 | 0.86 | MASP2 (0.47) | KLKB1MASP2KLK1NAMPTFPR2 | |
| SCHEMBL3137935 | 0.86 | KLKB1 (0.53) | KLKB1MASP2KLK1FPR2FCER2 | |
| SCHEMBL3137925 | 0.86 | KLKB1 (0.53) | KLKB1MASP2KLK1FPR2FCER2 | |
| SCHEMBL3149464 | 0.84 | FURIN (0.45) | KLKB1MASP2KLK1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | KLKB1 3491/4885MASP2 3039/4885KLK1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.